Physicians' Academy for Cardiovascular Education

GLP-1 analog reduces major CV outcomes in patients with atherosclerotic poly-vascular disease

Literature - May 16, 2018 - Verma S, et al. - Circulation 2018
Patients with T2DM and atherosclerotic poly-vascular disease have a higher CV risk than patients with single vascular disease, and in both groups liraglutide consistently reduced major CV outcomes.

Patients with T2DM and atherosclerotic poly-vascular disease have a higher CV risk than patients with single vascular disease, and in both groups liraglutide consistently reduced major CV outcomes.

Simple malnutrition scores predict mortality in HF

Literature - May 16, 2018 - Sze S, et al. - J Am Coll Cardiol HF 2018
Moderate and severe malnutrition in HF patients, assessed with simple malnutrition scores, was associated with higher all-cause mortality.

Moderate and severe malnutrition in HF patients, assessed with simple malnutrition scores, was associated with higher all-cause mortality.

Folic acid treatment reduces the risk of stroke in hypertensive patients

Literature - May 16, 2018 - Kong X et al. - J Am Coll Cardiol 2018
Patients with hypertension with low platelet counts and high total homocysteine levels, which may promote platelet adherence, had the highest risk of first stroke, and this risk was reduced with folic acid treatment.

Patients with hypertension with low platelet counts and high total homocysteine levels, which may promote platelet adherence, had the highest risk of first stroke, and this risk was reduced with folic acid treatment.

Emerging approaches to dyslipidemia management beyond LDL-c

3' education - Mar. 9, 2018 - VBWG at ACC 2018, Orlando, FL, USA - Eliot Brinton, Salt Lake City, UT, USA
Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c.. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.

VBWG at ACC 2018 Several novel targets have been discovered and new lipid-modifying therapies are being developed to prevent CVD, beyond LDL-c. Elliot Brinton discusses several of these, including omega-3 prescriptions, pemafibrate, apoC3, Lp(a), and shares the first trial results.

Clinical trials in diabetes and CVD: What did we learn?

Expert Meeting on CVD & T2DM

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya
Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.

Filippo Crea, Angelyn Bethel and Eduard Montanya discuss the safety and efficacy results of recent trials evaluating GLP-1 RAs and SGLT2 inhibitors, and whether the observed effects represent a class effect or not.

PCSK9 RNA interference causes significant and sustained lipid reductions

Literature - May 9, 2018 - Ray KK et al. - Circulation 2018

Inhibition of hepatic PCSK9 synthesis with the small interfering RNA inclisiran led to significant reductions of non-HDL-c and apoB, and increases of HDL-c, which were sustained up to day 180.

BNP also predicts mortality in patients without heart failure

Literature - May 9, 2018 - York MK et al. - J Am Coll Cardiol 2018

BNP is a strong predictor of all-cause death in patients with and without HF, and the risk of death associated with elevated BNP levels is similar between patients with and those without HF.

Electric cars safe for patients with CIEDs

Literature - May 8, 2018 - Lennerz C et al. - Ann Intern Med. 2018

Electric and magnetic fields generated during operation and charging of electric cars did not affect the function or programming of cardiac implantable electronic devices.

Cannabis use associated with lower AF risk in heart failure

Literature - May 8, 2018 - Adegbala O, et al. - Am J Cardiol 2018

In a retrospective analysis of a healthcare cost and utilization database, cannabis use was associated with a lower AF risk in hospitalized heart failure patients.

Ambulatory BP stronger predictor of mortality than clinic BP

Literature - May 8, 2018 - Banegas JR, et al. - N Engl J Med 2018
24-hour, daytime, and nighttime ambulatory systolic blood pressure measurements were better predictors of all-cause and CV mortality compared with blood pressure measurements in the clinic.

24-hour, daytime, and nighttime ambulatory systolic blood pressure measurements were better predictors of all-cause and CV mortality compared with blood pressure measurements in the clinic.

How to manage DOAC-related bleeding

10' education - Mar. 8, 2018 - Prof. Menno Huisman and dr. Alexander Cohen
To what extent does bleeding on VKA differ from on DOAC treatment? Menno Huisman and Alexander Cohen discuss the management and outcomes of bleeding on direct oral coagulation therapy.

To what extent does bleeding on VKA differ from on DOAC treatment? Menno Huisman and Alexander Cohen discuss the management and outcomes of bleeding on direct oral coagulation therapy.

First antidote for reversal of Factor Xa inhibitors receives FDA approval

News - May 7, 2018

FDA has approved andexanet alfa, to reverse anticoagulation induced by rivaroxaban or apixaban, in case of life-threatening or uncontrolled bleeding